Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2007

01-12-2007

Tumour vascularization: sprouting angiogenesis and beyond

Authors: Femke Hillen, Arjan W. Griffioen

Published in: Cancer and Metastasis Reviews | Issue 3-4/2007

Login to get access

Abstract

Tumour angiogenesis is a fast growing domain in tumour biology. Many growth factors and mechanisms have been unravelled. For almost 30 years, the sprouting of new vessels out of existing ones was considered as an exclusive way of tumour vascularisation. However, over the last years several additional mechanisms have been identified. With the discovery of the contribution of intussusceptive angiogenesis, recruitment of endothelial progenitor cells, vessel co-option, vasculogenic mimicry and lymphangiogenesis to tumour growth, anti-tumour targeting strategies will be more complex than initially thought. This review highlights these processes and intervention as a potential application in cancer therapy. It is concluded that future anti-vascular therapies might be most beneficial when based on multimodal anti-angiogenic, anti-vasculogenic mimicry and anti-lymphangiogenic strategies.
Literature
1.
Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249–57.PubMed
2.
Martin, A., Komada, M. R., & Sane, D. C. (2003). Abnormal angiogenesis in diabetes mellitus. Medicinal Research Reviews, 23, 117–45.PubMed
3.
Koch, A. E. (2003). Angiogenesis as a target in rheumatoid arthritis. Annals of the Rheumatic Diseases, 62 Suppl 2, ii60–7.PubMed
4.
Cao, Y., Hong, A., Schulten, H., & Post, M. J. (2005). Update on therapeutic neovascularization. Cardiovascular Research, 65, 639–48.PubMed
5.
Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 438, 932–36.PubMed
6.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–0.PubMed
7.
Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors. Nature Medicine, 9, 669–76PubMed
8.
Jain, R. K. (2003). Molecular regulation of vessel maturation. Nature Medicine, 9, 685–93.PubMed
9.
Kerbel, R. S. (2000). Tumor angiogenesis: Past, present and the near future. Carcinogenesis, 21, 505–15.PubMed
10.
Itoh, N., & Ornitz, D. M. (2004). Evolution of the Fgf and Fgfr gene families. Trends in Genetics, 20, 563–69.PubMed
11.
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Reviews, 16, 159–78.PubMed
12.
Gross, J. L., Herblin, W. F., Dusak, B. A., Czerniak, P., Diamond, M. D., Sun, T., et al. (1993). Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. Journal of the National Cancer Institute, 85, 121–31.PubMed
13.
Wang, Y. & Becker, D. (1997). Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Medicine, 3, 887–93.PubMed
14.
Ferrara, N., & Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocrine Reviews, 18, 4–5.PubMed
15.
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737–44.PubMed
16.
Iyer, S., & Acharya, K. R. (2002). Role of placenta growth factor in cardiovascular health. Trends in Cardiovascular Medicine, 12, 128–34.PubMed
17.
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., et al. (2001). G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine, 7, 575–83.PubMed
18.
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., et al. (1996). Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87, 1161–169.PubMed
19.
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., et al. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55–0.PubMed
20.
Elliott, R. L., & Blobe, G. C. (2005). Role of transforming growth factor Beta in human cancer. Journal of Clinical Oncology, 23, 2078–093.PubMed
21.
Armulik, A., Abramsson, A., & Betsholtz, C. (2005). Endothelial/pericyte interactions. Circulation Research, 97, 512–23.PubMed
22.
Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., et al. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology, 151, 1523–530.PubMed
23.
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003). IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. Journal of Immunology, 170, 3369–376.
24.
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. Journal of Cell Biology, 161, 1163–177.PubMed
25.
Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q., Brekken, R. A., Thorpe, P. E., et al. (2002). Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene, 21, 7011–026.PubMed
26.
Bielenberg, D. R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C. C., et al. (2004). Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. Journal of Clinical Investigation, 114, 1260–271.PubMed
27.
Conrotto, P., Valdembri, D., Corso, S., Serini, G., Tamagnone, L., Comoglio, P. M., et al. (2005). Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood, 105, 4321–329.PubMed
28.
Wang, B., Xiao, Y., Ding, B. B., Zhang, N., Yuan, X., Gui, L., et al. (2003). Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell, 4, 19–9.PubMed
29.
Arakawa, H. (2004). Netrin-1 and its receptors in tumorigenesis. Natural Reviews Cancer, 4, 978–87.
30.
Rehman, A. O., & Wang, C. Y. (2006). Notch signaling in the regulation of tumor angiogenesis. Trends in Cell Biology, 16, 293–00.PubMed
31.
Rastinejad, F., Polverini, P. J., & Bouck, N. P. (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56, 345–55.PubMed
32.
Ferrara, N., Clapp, C., & Weiner, R. (1991). The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology, 129, 896–00.PubMed
33.
Kolber, D. L., Knisely, T. L., and Maione, T. E. (1995). Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. Journal of National Cancer Institute, 87, 304–09.PubMed
34.
Luster, A. D., Greenberg, S. M., & Leder, P. (1995). The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. Journal of Experimental Medicine, 182, 219–31.PubMed
35.
O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315–28.PubMed
36.
O’Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., et al. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277–85.PubMed
37.
van der Schaft, D. W., Toebes, E. A., Haseman, J. R., Mayo, K. H., & Griffioen, A. W. (2000). Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood, 96, 176–81.PubMed
38.
Maeshima, Y., Colorado, P. C., Torre, A., Holthaus, K. A., Grunkemeyer, J. A., Ericksen, M. B., et al. (2000). Distinct antitumor properties of a type IV collagen domain derived from basement membrane. Journal of Biological Chemistry, 275, 21340–1348.PubMed
39.
Tabruyn, S. P., & Griffioen, A. W. (2007). Molecular pathways of angiogenesis inhibition. Biochemical and Biophysical Research Communications, 355, 1–.PubMed
40.
Marx, J. Angiogenesis. (2003). A boost for tumor starvation. Science, 301, 452–54.PubMed
41.
Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature, 438, 967–74.PubMed
42.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335–342.PubMed
43.
Glusker, P., Recht, L., and Lane, B. (2006). Reversible posterior leukoencephalopathy syndrome and bevacizumab. New England Journal of Medicine, 354, 980–82; discussion 980–82.PubMed
44.
Ozcan, C., Wong, S. J., and Hari, P. (2006). Reversible posterior leukoencephalopathy syndrome and bevacizumab. New England Journal of Medicine, 354, 980–82, discussion 980–82.PubMed
45.
Alitalo, K., Tammela, T., & Petrova, T. V. (2005). Lymphangiogenesis in development and human disease. Nature, 438, 946–53.PubMed
46.
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002). Effect of p53 status on tumor response to antiangiogenic therapy. Science, 295, 1526–528.PubMed
47.
Glade Bender, J., Cooney, E. M., Kandel, J. J., & Yamashiro, D. J. (2004). Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resistance Updates, 7, 289–00.PubMed
48.
Hida, K., Hida, Y., Amin, D. N., Flint, A. F., Panigrahy, D., Morton, C. C., et al. (2004). Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Research, 64, 8249–255.PubMed
49.
Streubel, B., Chott, A., Huber, D., Exner, M., Jager, U., Wagner, O., et al. (2004). Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. New England Journal of Medicine, 351, 250–59.PubMed
50.
Caduff, J. H., Fischer, L. C., & Burri, P. H. (1986). Scanning electron microscope study of the developing microvasculature in the postnatal rat lung. Anatomical Record, 216, 154–64.PubMed
51.
Burri, P. H., Hlushchuk, R., & Djonov, V. (2004). Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance. Developmental Dynamics, 231, 474–88.PubMed
52.
Djonov, V. G., Kurz, H., & Burri, P. H. (2002). Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Developmental Dynamics, 224, 391–02.PubMed
53.
Patan, S., Haenni, B., & Burri, P. H. (1993). Evidence for intussusceptive capillary growth in the chicken chorio-allantoic membrane (CAM). Anatomy and Embryology (Berl), 187, 121–30.
54.
Patan, S., Munn, L. L., & Jain, R. K. (1996). Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis. Microvascular Research, 51, 260–72.PubMed
55.
Djonov, V., Andres, A. C., & Ziemiecki, A. (2001). Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microscopy Research and Technique, 52, 182–89.PubMed
56.
Ribatti, D., Nico, B., Floris, C., Mangieri, D., Piras, F., Ennas, M. G., et al. (2005). Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncology Reports, 14, 81–4.PubMed
57.
Oh, S. J., Kurz, H., Christ, B., & Wilting, J. (1998). Platelet-derived growth factor-B induces transformation of fibrocytes into spindle-shaped myofibroblasts in vivo. Histochemistry and Cell Biology, 109, 349–57.PubMed
58.
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., et al. (1999). Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science, 286, 2511–514.PubMed
59.
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, 964–67.PubMed
60.
Kalka, C., Masuda, H., Takahashi, T., Kalka-Moll, W. M., Silver, M., Kearney, M., et al. (2000). Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proceedings of the National Academy of Sciences of the United States of America, 3422–427.
61.
Lin, Y., Weisdorf, D. J., Solovey, A., & Hebbel, R. P. (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 105, 71–7.PubMed
62.
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109, 625–37.PubMed
63.
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., et al. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO Journal, 18, 3964–972.PubMed
64.
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., et al. (2002). Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Medicine, 8, 841–49.PubMed
65.
Moore, M. A., Hattori, K., Heissig, B., Shieh, J. H., Dias, S., Crystal, R. G., and Rafii, S. (2001). Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Annals of the New York Academy of Sciences, 938, 36–5; discussion 45–7.PubMedCrossRef
66.
Aicher, A., Heeschen, C., Mildner-Rihm, C., Urbich, C., Ihling, C., Technau-Ihling, K., et al. (2003). Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Medicine, 9, 1370–376.PubMed
67.
Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., et al. (1999). Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Medicine, 5, 434–38.PubMed
68.
Vajkoczy, P., Blum, S., Lamparter, M., Mailhammer, R., Erber, R., Engelhardt, B., et al. (2003). Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. Journal of Experimental Medicine, 197, 1755–765.PubMed
69.
Deb, A., Skelding, K. A., Wang, S., Reeder, M., Simper, D., & Caplice, N. M. (2004). Integrin profile and in vivo homing of human smooth muscle progenitor cells. Circulation, 110, 2673–677.PubMed
70.
Chavakis, E., Hain, A., Vinci, M., Carmona, G., Bianchi, M. E., Vajkoczy, P., et al. (2007). High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circulation Research, 100, 204–12.PubMed
71.
Liao, F., Huynh, H. K., Eiroa, A., Greene, T., Polizzi, E., & Muller, W. A. (1995). Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. Journal of Experimental Medicine, 182, 1337–343.PubMed
72.
Schenkel, A. R., Mamdouh, Z., Chen, X., Liebman, R. M., & Muller, W. A. (2002). CD99 plays a major role in the migration of monocytes through endothelial junctions. Nature Immunology, 3, 143–50.PubMed
73.
Gehling, U. M., Ergun, S., Schumacher, U., Wagener, C., Pantel, K., Otte, M., et al. (2000). In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 95, 3106–112.PubMed
74.
Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., et al. (1999). Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation Research, 85, 221–28.PubMed
75.
Lyden, D., Young, A. Z., Zagzag, D., Yan, W., Gerald, W., O’Reilly, R., et al. (1999). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature, 401, 670–77.PubMed
76.
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine, 7, 1194–201.PubMed
77.
Machein, M. R., Renninger, S., de Lima-Hahn, E., & Plate, K. H. (2003). Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathology, 13, 582–97.PubMedCrossRef
78.
Ruzinova, M. B., Schoer, R. A., Gerald, W., Egan, J. E., Pandolfi, P. P., Rafii, S., et al. (2003). Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell, 4, 277–89.PubMed
79.
Gothert, J. R., Gustin, S. E., van Eekelen, J. A., Schmidt, U., Hall, M. A., Jane, S. M., et al. (2004). Genetically tagging endothelial cells in vivo: Bone marrow-derived cells do not contribute to tumor endothelium. Blood, 104, 1769–777.PubMed
80.
Rajantie, I., Ilmonen, M., Alminaite, A., Ozerdem, U., Alitalo, K., & Salven, P. (2004). Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood, 104, 2084–086.PubMed
81.
Peters, B. A., Diaz, L. A., Polyak, K., Meszler, L., Romans, K., Guinan, E. C., et al. (2005). Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nature Medicine, 11, 261–62.PubMed
82.
Larrivee, B., Niessen, K., Pollet, I., Corbel, S. Y., Long, M., Rossi, F. M., et al. (2005). Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. Journal of Immunology, 175, 2890–899.
83.
Sussman, L. K., Upalakalin, J. N., Roberts, M. J., Kocher, O., & Benjamin, L. E. (2003). Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biology & Therapy, 2, 255–56.
84.
Kim, H. K., Song, K. S., Kim, H. O., Chung, J. H., Lee, K. R., Lee, Y. J., et al. (2003). Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Letter, 198, 83–8.
85.
Capillo, M., Mancuso, P., Gobbi, A., Monestiroli, S., Pruneri, G., Dell’Agnola, C., et al. (2003). Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clinical Cancer Research, 9, 377–82.PubMed
86.
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz, T., et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell, 7, 101–11.PubMed
87.
Arafat, W. O., Casado, E., Wang, M., Alvarez, R. D., Siegal, G. P., Glorioso, J. C., et al. (2000). Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clinical Cancer Research, 6, 4442–448.PubMed
88.
Ingram, D. A., Caplice, N. M., & Yoder, M. C. (2005). Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood, 106, 1525–531.PubMed
89.
Wesseling, P., van der Laak, J. A., de Leeuw, H., Ruiter, D. J., & Burger, P. C. (1994). Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. Journal of Neurosurgery, 81, 902–09.PubMed
90.
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine, 1, 149–53.PubMed
91.
Pezzella, F., Pastorino, U., Tagliabue, E., Andreola, S., Sozzi, G., Gasparini, G., et al. (1997). Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. American Journal of Pathology, 151, 1417–423.PubMed
92.
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., et al. (1999). Vessel co-option, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 284, 1994–998.PubMed
93.
Zhang, L., Yang, N., Park, J. W., Katsaros, D., Fracchioli, S., Cao, G., et al. (2003). Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Research, 63, 3403–412.PubMed
94.
Dome, B., Paku, S., Somlai, B., & Timar, J. (2002). Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. Journal of Pathology, 197, 355–62.PubMed
95.
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., et al. (2002). Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 99, 11399–1404.PubMed
96.
Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., et al. (2001). Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Research, 61, 6624–628.PubMed
97.
Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M., Pe’er, J., et al. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. American Journal of Pathology, 155, 739–52.PubMed
98.
Folberg, R., Rummelt, V., Parys-Van Ginderdeuren, R., Hwang, T., Woolson, R. F., Pe’er, J., et al. (1993). The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology, 100, 1389–398.PubMed
99.
Hendrix, M. J., Seftor, E. A., Hess, A. R., & Seftor, R. E. (2003). Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nature Reviews Cancer, 3, 411–21.PubMed
100.
Seftor, R. E., Seftor, E. A., Koshikawa, N., Meltzer, P. S., Gardner, L. M., Bilban, M., et al. (2001). Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Research, 61, 6322–327.PubMed
101.
Hendrix, M. J., Seftor, E. A., Meltzer, P. S., Gardner, L. M., Hess, A. R., Kirschmann, D. A., et al. (2001). Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry. Proceedings of the National Academy of Sciences of the United States of America, 98, 8018–023.PubMed
102.
Hess, A. R., Postovit, L. M., Margaryan, N. V., Seftor, E. A., Schneider, G. B., Seftor, R. E., et al. (2005). Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Research, 65, 9851–860.PubMed
103.
Basu, G. D., Liang, W. S., Stephan, D. A., Wegener, L. T., Conley, C. R., Pockaj, B. A., et al. (2006). A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Research, 8, R69.PubMed
104.
Rothhammer, T., Bataille, F., Spruss, T., Eissner, G., & Bosserhoff, A. K. (2007). Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene, 26, 4158–170.PubMed
105.
Xi, Y., Nakajima, G., Hamil, T., Fodstad, O., Riker, A., & Ju, J. (2006). Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Molecular Cancer Therapeutics, 5, 3078–084.PubMed
106.
Topczewska, J. M., Postovit, L. M., Margaryan, N. V., Sam, A., Hess, A. R., Wheaton, W. W., et al. (2006). Embryonic and tumorigenic pathways converge via Nodal signaling: Role in melanoma aggressiveness. Nature Medicine, 12, 925–32.PubMed
107.
Seftor, E. A., Brown, K. M., Chin, L., Kirschmann, D. A., Wheaton, W. W., Protopopov, A., et al. (2005). Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Research, 65, 10164–0169.PubMed
108.
Rofstad, E. K., Rasmussen, H., Galappathi, K., Mathiesen, B., Nilsen, K., & Graff, B. A. (2002). Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Research, 62, 1847–853.PubMed
109.
Bedogni, B., Welford, S. M., Cassarino, D. S., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2005). The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell, 8, 443–54.PubMed
110.
Rybak, S. M., Sanovich, E., Hollingshead, M. G., Borgel, S. D., Newton, D. L., Melillo, G., et al. (2003). “Vasocrine–formation of tumor cell-lined vascular spaces: Implications for rational design of antiangiogenic therapies. Cancer Research, 63, 2812–819.PubMed
111.
van der Schaft, D. W., Hillen, F., Pauwels, P., Kirschmann, D. A., Castermans, K., Egbrink, M. G., et al. (2005). Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Research, 65, 11520–1528.PubMed
112.
Sun, B., Zhang, D., Zhang, S., Zhang, W., Guo, H., & Zhao, X. (2007). Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Letter, 249, 188–97.
113.
Clarijs, R., Otte-Holler, I., Ruiter, D. J., & de Waal, R. M. (2002). Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Investigative Ophthalmology and Visual Science, 43, 912–18.PubMed
114.
Shirakawa, K., Kobayashi, H., Heike, Y., Kawamoto, S., Brechbiel, M. W., Kasumi, F., et al. (2002). Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Research, 62, 560–66.PubMed
115.
Ruf, W., Seftor, E. A., Petrovan, R. J., Weiss, R. M., Gruman, L. M., Margaryan, N. V., et al. (2003). Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Research, 63, 5381–389.PubMed
116.
Frenkel, S., Barzel, I., Levy, J., Lin, A. Y., Bartsch, D. U., Majumdar, D., Folberg, R., & Pe’er, J. (2007). Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye, in press, DOI 10.​1038/​sj.​eye.​6702783.
117.
Thies, A., Mangold, U., Moll, I., & Schumacher, U. (2001). PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. Journal of Pathology, 195, 537–42.PubMed
118.
Lee, Y. J., Nagai, N., Siar, C. H., Nakano, K., Nagatsuka, H., Tsujigiwa, H., et al. (2002). Angioarchitecture of primary oral malignant melanomas. Journal of Histochemistry and Cytochemistry, 50, 1555–562.PubMed
119.
Sharma, N., Seftor, R. E., Seftor, E. A., Gruman, L. M., Heidger, P. M., Jr., Cohen, M. B., et al. (2002). Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role in vasculogenic mimicry. Prostate, 50, 189–01.PubMed
120.
Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. M., Heidger, P. M., Buller, R. E., et al. (2001). Molecular determinants of ovarian cancer plasticity. American Journal of Pathology, 158, 1279–288.PubMed
121.
Sun, B., Zhang, S., Zhang, D., Du, J., Guo, H., Zhao, X., et al. (2006). Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncology Reports, 16, 693–98.PubMed
122.
Fujimoto, A., Onodera, H., Mori, A., Nagayama, S., Yonenaga, Y., & Tachibana, T. (2006). Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. Anticancer Research, 26, 59–9.PubMed
123.
Sun, B., Zhang, S., Zhao, X., Zhang, W., & Hao, X. (2004). Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. International Journal of Oncology, 25, 1609–614.PubMed
124.
Cai, X. S., Jia, Y. W., Mei, J., & Tang, R. Y. (2004). Tumor blood vessels formation in osteosarcoma: Vasculogenesis mimicry. Chinese Medical Journal (Engl), 117, 94–8.
125.
Yue, W. Y. & Chen, Z. P. (2005). Does vasculogenic mimicry exist in astrocytoma? Journal of Histochemistry and Cytochemistry, 53, 997–002.PubMed
126.
Favier, J., Plouin, P. F., Corvol, P., & Gasc, J. M. (2002). Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors. American Journal of Pathology, 161, 1235–246.PubMed
127.
Seftor, R. E., Seftor, E. A., Kirschmann, D. A., & Hendrix, M. J. (2002). Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Molecular Cancer Therapeutics, 1, 1173–179.PubMed
128.
Rudek, M. A., Horne, M., Figg, W. D., Dahut, W., Dyer, V., Pluda, J. M., et al. (2001). Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. American Journal of Hematology, 67, 51–3.PubMed
129.
Ghate, J. V., Turner, M. L., Rudek, M. A., Figg, W. D., Dahut, W., Dyer, V., et al. (2001). Drug-induced lupus associated with COL-3: Report of 3 cases. Archives of Dermatology, 137, 471–74.PubMed
130.
van der Schaft, D. W., Seftor, R. E., Seftor, E. A., Hess, A. R., Gruman, L. M., Kirschmann, D. A., et al. (2004). Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. Journal of the National Cancer Institute, 96, 1473–477.PubMedCrossRef
131.
Pepper, M. S., & Skobe, M. (2003). Lymphatic endothelium: Morphological, molecular and functional properties. Journal of Cell Biology, 163, 209–13.PubMed
132.
Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–52.PubMed
133.
Podgrabinska, S., Braun, P., Velasco, P., Kloos, B., Pepper, M. S., & Skobe, M. (2002). Molecular characterization of lymphatic endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 16069–6074.PubMed
134.
Kaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh, V. W., Fang, G. H., Dumont, D., et al. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proceedings of the National Academy of Sciences of the United States of America, 92, 3566–570.PubMed
135.
Banerji, S., Ni, J., Wang, S. X., Clasper, S., Su, J., Tammi, R., et al. (1999). LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. Journal of Cell Biology, 144, 789–01.PubMed
136.
Breiteneder-Geleff, S., Soleiman, A., Kowalski, H., Horvat, R., Amann, G., Kriehuber, E., et al. (1999). Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. American Journal of Pathology, 154, 385–94.PubMed
137.
Oliver, G., & Detmar, M. (2002). The rediscovery of the lymphatic system: Old and new insights into the development and biological function of the lymphatic vasculature. Genes & Development, 16, 773–83.
138.
Joukov, V., Kumar, V., Sorsa, T., Arighi, E., Weich, H., Saksela, O., et al. (1998). A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. Journal of Biological Chemistry, 273, 6599–602.PubMed
139.
Baldwin, M. E., Halford, M. M., Roufail, S., Williams, R. A., Hibbs, M. L., Grail, D., et al. (2005). Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Molular and Cellular Biology, 25, 2441–449.PubMed
140.
Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., et al. (2004). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunology, 5, 74–0.PubMed
141.
Makinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E. C., et al. (2001). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO Journal, 20, 4762–773.PubMed
142.
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., et al. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine, 7, 192–98.PubMed
143.
Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Williams, R. A., Prevo, R., et al. (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Medicine, 7, 186–91.PubMed
144.
Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., et al. (2002). Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. Journal of Experimental Medicine, 196, 1497–506.PubMed
145.
Chang, L. K., Garcia-Cardena, G., Farnebo, F., Fannon, M., Chen, E. J., Butterfield, C., et al. (2004). Dose-dependent response of FGF-2 for lymphangiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 101, 11658–1663.PubMed
146.
Cao, R., Bjorndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., et al. (2004). PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell, 6, 333–45.PubMed
147.
Anan, K., Morisaki, T., Katano, M., Ikubo, A., Kitsuki, H., Uchiyama, A., et al. (1996). Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery, 119, 333–39.PubMed
148.
Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., et al. (2002). Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell, 3, 411–23.PubMed
149.
Morisada, T., Oike, Y., Yamada, Y., Urano, T., Akao, M., Kubota, Y., et al. (2005). Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood, 105, 4649–656.PubMed
150.
Yuan, L., Moyon, D., Pardanaud, L., Breant, C., Karkkainen, M. J., Alitalo, K., et al. (2002). Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development, 129, 4797–806.PubMed
151.
Kajiya, K., Hirakawa, S., Ma, B., Drinnenberg, I., & Detmar, M. (2005). Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO Journal, 24, 2885–895.PubMed
152.
Bjorndahl, M., Cao, R., Nissen, L. J., Clasper, S., Johnson, L. A., Xue, Y., et al. (2005). Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 102, 15593–5598.PubMed
153.
Saharinen, P., Tammela, T., Karkkainen, M. J., & Alitalo, K. (2004). Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends in Immunology, 25, 387–95.PubMed
154.
Ji, R. C. (2006). Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer and Metastasis Reviews, 25, 677–94.PubMed
155.
Achen, M. G., Mann, G. B., & Stacker, S. A. (2006). Targeting lymphangiogenesis to prevent tumour metastasis. British Journal of Cancer, 94, 1355–360.PubMed
156.
Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E., & Alitalo, K. (2002). Lymphangiogenesis and cancer metastasis. Nature Reviews Cancer, 2, 573–83.
157.
Schoppmann, S. F., Bayer, G., Aumayr, K., Taucher, S., Geleff, S., Rudas, M., et al. (2004). Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Annals of Surgery, 240, 306–12.PubMed
158.
Lee, A. H., Pinder, S. E., Macmillan, R. D., Mitchell, M., Ellis, I. O., Elston, C. W., et al. (2006). Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. European Journal of Cancer, 42, 357–62.PubMed
159.
van der Schaft, D. W., Pauwels, P., Hulsmans, S., Zimmermann, M., van de Poll-Franse, L. V., & Griffioen, A. W. (2007). Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Letter, 254, 128–36.
160.
Arigami, T., Natsugoe, S., Uenosono, Y., Arima, H., Mataki, Y., Ehi, K., et al. (2005). Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. British Journal of Cancer, 93, 688–93.PubMed
161.
Lotan, Y., Gupta, A., Shariat, S. F., Palapattu, G. S., Vazina, A., Karakiewicz, P. I., et al. (2005). Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. Journal of Clinical Oncology, 23, 6533–539.PubMed
162.
Karpanen, T., Egeblad, M., Karkkainen, M. J., Kubo, H., Yla-Herttuala, S., Jaattela, M., et al. (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Research, 61, 1786–790.PubMed
163.
Szuba, A., Skobe, M., Karkkainen, M. J., Shin, W. S., Beynet, D. P., Rockson, N. B., et al. (2002). Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB Journal, 16, 1985–987.PubMed
164.
Zhang, L., Giraudo, E., Hoffman, J. A., Hanahan, D., & Ruoslahti, E. (2006). Lymphatic zip codes in premalignant lesions and tumors. Cancer Research, 66, 5696–706.PubMed
165.
Jain, R. K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307, 58–2.PubMed
Metadata
Title
Tumour vascularization: sprouting angiogenesis and beyond
Authors
Femke Hillen
Arjan W. Griffioen
Publication date
01-12-2007
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2007
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-007-9094-7

Other articles of this Issue 3-4/2007

Cancer and Metastasis Reviews 3-4/2007 Go to the issue

OriginalPaper

Metastasis: the seed and soil theory gains identity

OriginalPaper

Dietary fat’gene interactions in cancer

OriginalPaper

RECK—a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer

OriginalPaper

Endogenous growth inhibition of angiogenesis in brain tumors

OriginalPaper

The role of autocrine motility factor in tumor and tumor microenvironment

OriginalPaper

Lipoxygenase metabolism: roles in tumor progression and survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits